Discussions

Adding to the challenge is the current lack of widespread screening programs for early stage T1DM in the general population, making it difficult to identify all patients who may benefit from teplizumab.

What we often miss is telling patients what to do when things go wrong.

Dr. Robert Dickson writes about a patient who presented with a recurring rash that had puzzled several previous physicians, including a dermatologist.

Avoiding participating in online ratings doesn’t protect your dignity—Dr. Varun Bajaj argues it just hands your narrative to the angriest voices in the room.

Many Canadian colleagues and I have had to travel across continents to be part of this unique pharmacy gathering. This year, it’s happening in our backyard.

Two neuroscientists outline the risks of the condition, which affects more than a billion people worldwide, and why we need better diagnosis.

See what your colleagues say. Take our weekly doctor poll.

Wait, doc, what’s this all about? You’re asking people not to move to where you live?!?

In this article re-published from the Neighbourhood Pharmacies' quarterly publication, The Gazette, Karen Welds takes a deep dive into the staffing shortage and what can be done about it.

After watching a string of family gatherings get swallowed by screen time, Dr. Howard Goldstein wonders what this advancement in technology is costing us.